Deep brain stimulation (DBS) as a therapeutic approach in gait disorders: What does it bring to the table?

Pourahmad, Ramtin; Saleki, Kiarash; Esmaili, Mohammadreza; Abdollahi, Arian; Alijanizadeh, Parsa; Gholinejad, Mehrad Zare; Banazadeh, Mohammad; Ahmadi, Mona

doi:10.1016/j.ibneur.2023.05.008

Cited by 2 publications

(2 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further research on more subjects to evaluate the longer-term therapeutic effects of CR DBS will be needed to confirm our findings. Additional studies (Conway et al, 2021 ; Seger et al, 2021 ; Su et al, 2022 ; Cavallieri et al, 2023 ; Pourahmad et al, 2023 ) to compare the effect of CR DBS on gait with that of traditional DBS will also be required for the clinical translation of CR DBS.…”

Section: Discussionmentioning

confidence: 99%

Effect of subthalamic coordinated reset deep brain stimulation on Parkinsonian gait

Bosley,

Luo,

Amoozegar

et al. 2023

Front. Neuroinform.

View full text Add to dashboard Cite

IntroductionCoordinated Reset Deep Brain Stimulation (CR DBS) is a novel DBS approach for treating Parkinson's disease (PD) that uses lower levels of burst stimulation through multiple contacts of the DBS lead. Though CR DBS has been demonstrated to have sustained therapeutic effects on rigidity, tremor, bradykinesia, and akinesia following cessation of stimulation, i.e., carryover effect, its effect on Parkinsonian gait has not been well studied. Impaired gait is a disabling symptom of PD, often associated with a higher risk of falling and a reduced quality of life. The goal of this study was to explore the carryover effect of subthalamic CR DBS on Parkinsonian gait.MethodsThree non-human primates (NHPs) were rendered Parkinsonian and implanted with a DBS lead in the subthalamic nucleus (STN). For each animal, STN CR DBS was delivered for several hours per day across five consecutive days. A clinical rating scale modified for NHP use (mUPDRS) was administered every morning to monitor the carryover effect of CR DBS on rigidity, tremor, akinesia, and bradykinesia. Gait was assessed quantitatively before and after STN CR DBS. The stride length and swing speed were calculated and compared to the baseline, pre-stimulation condition.ResultsIn all three animals, carryover improvements in rigidity, bradykinesia, and akinesia were observed after CR DBS. Increased swing speed was observed in all the animals; however, improvement in stride length was only observed in NHP B2. In addition, STN CR DBS using two different burst frequencies was evaluated in NHP B2, and differential effects on the mUPDRS score and gait were observed.DiscussionAlthough preliminary, our results indicate that STN CR DBS can improve Parkinsonian gait together with other motor signs when stimulation parameters are properly selected. This study further supports the continued development of CR DBS as a novel therapy for PD and highlights the importance of parameter selection in its clinical application.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of subthalamic coordinated reset deep brain stimulation on Parkinsonian gait

Bosley,

Luo,

Amoozegar

et al. 2023

Front. Neuroinform.

View full text Add to dashboard Cite

show abstract

“…Deep brain stimulation, which proved to be a gold-standard treatment for some advancedstage PD patients, involves the surgical implantation of electrodes. Thalamic stimulation, pedunculopontine nucleus stimulation, and pallidal stimulation are examples of deep brain stimulation [17]. It is beneficial to early-stage PD patients with improvement in tremors and for treating motor fluctuations and symptoms such as tremors, stiffness, and bradykinesia.…”

Section: Management Of Parkinson's Diseasementioning

confidence: 99%

Tiny Carriers, Tremendous Hope: Nanomedicine in the Fight against Parkinson’s

Dogra,

Jakhmola Mani,

Pande Katare

2024

JDAD

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms due to the loss of dopamine-producing neurons and the presence of Lewy bodies in the brain. While current treatments such as dopamine replacement with levodopa and deep brain stimulation mainly manage symptoms and do not stop disease progression, recent advancements in nanomedicine provide promising new therapy options. These include drug-loaded nanocarriers that improve drug delivery to the brain, enhancing effectiveness and reducing side effects. This review explores novel nanomedical approaches like solid lipid nanocarriers (SLNs), which could improve drug profiles and decrease the adverse effects seen with traditional PD treatments. Additionally, it discusses the challenge of crossing the blood–brain barrier, which is crucial for treating central nervous system disorders, and how nanocarriers facilitate targeted brain delivery. Despite these advancements, the review emphasizes more research into the safety and long-term impacts of nanomedicine in PD, highlighting the challenge of moving these treatments from lab to clinical use.

show abstract

Deep brain stimulation (DBS) as a therapeutic approach in gait disorders: What does it bring to the table?

Cited by 2 publications

References 113 publications

Effect of subthalamic coordinated reset deep brain stimulation on Parkinsonian gait

Effect of subthalamic coordinated reset deep brain stimulation on Parkinsonian gait

Tiny Carriers, Tremendous Hope: Nanomedicine in the Fight against Parkinson’s

Contact Info

Product

Resources

About